Health ❯ Healthcare ❯ Patient Outcomes

Efficacy Studies

SYNCHRONIZE-1 Trial Symptomatic Recurrent VTE TOGETHER-PsA Trial Results Quality of Life Measurements GLOW2 Study Results Placebo Effect HbA1c Reduction Weight Management Survival Rates Visual Acuity

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Full results are slated for presentation at the American Diabetes Association meeting in June.

Kodiak’s Zenkuda Hits Phase 3 Goal in Diabetic Retinopathy Prompting Faster FDA Filing

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

CagriSema Beats Semaglutide on HbA1c and Weight at 68 Weeks in Type 2 Diabetes Trial

Large ADHD Trial Finds No Benefit From FDA-Cleared Trigeminal Stimulation Device

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Belite Bio’s Tinlarebant Cuts Stargardt Lesion Growth 36% in Phase 3 Trial

Aficamten Tops Metoprolol in Obstructive HCM as Mavacamten Misses in Nonobstructive Trial